For Investors

Press Releases

Press Releases

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Keyword Search

Date Title
October 21, 2020
Novan to Present at the Virtual Investor KOL Roundtable
October 14, 2020
Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2 in Human Airway Infection Model
September 24, 2020
Novan Strengthens Financial Leadership with Appointments of Chief Financial Officer and Seasoned Industry Executive to Board of Directors
September 14, 2020
Novan Provides Pipeline and Priority Development Programs Update
September 9, 2020
Novan to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 3, 2020
Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
August 31, 2020
Novan Initiates B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
July 28, 2020
Novan President and CEO, Paula Brown Stafford Named Chairman of the Board
July 23, 2020
Novan to Host Live Audio Webcast of 2020 Annual Meeting of Stockholders
June 25, 2020
Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial
June 24, 2020
Novan to Present at Virtual Life Sciences Investor Forum on June 25
April 30, 2020
Novan Announces Receipt of Written Minutes from Type C Meeting with FDA Regarding Development of SB206
April 20, 2020
Novan Announces Comprehensive Evaluation of Strategic and Financial Alternatives
April 3, 2020
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
March 26, 2020
Novan Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market
March 24, 2020
Novan Announces $8.0 Million Registered Direct Offering Priced At-the-Market
March 23, 2020
Novan Announces Data from B-SIMPLE Week 24 Safety Evaluation and COVID-19 Business Updates
March 3, 2020
Novan Announces Closing of $5.95 Million Public Offering, including Partial Exercise of the Underwriter’s Option to Purchase Additional Securities
February 27, 2020
Novan Announces Pricing of $5.5 Million Public Offering
February 27, 2020
Novan Announces Proposed Public Offering
February 20, 2020
Novan Receives Phase 2 NIH Federal Grant of Approximately $1.0 Million
February 6, 2020
Novan Provides SB206 Program and Business Update
January 2, 2020
Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum